drugset / Trial / NCT06415773
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Phase 3
Completed
367 enrolled
HighTide Biopharma Pty Ltd
Shenzhen HighTide Biopharmaceutical Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The goal of this clinical study is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone.
Timeline
- Start
- 2024-06-04
- Primary completion
- 2025-06-13
- Completion
- 2025-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |
| Subject | berberine ursodeoxycholate | Small molecule | 1000 mg | Oral |